{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T21:17:56Z","timestamp":1791839876616,"version":"4.3.4"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T00:00:00Z","timestamp":1749427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Pityriasis rubra pilaris (PRP) is a rare inflammatory dermatosis. There are limited data on its treatment with biologic therapies. We present a case series to evaluate the efficacy, time to primary response (TTPR) and tolerability of biologics in PRP management. A retrospective analysis of 11 patients with PRP treated with biologics at a tertiary Australian dermatology department was conducted. Patient demographics, prior therapies and treatment outcomes were reviewed. Biologics demonstrated variable efficacy: significant responses were seen with secukinumab (three of four, 75%), tildrakizumab (two of seven, 29%), ixekizumab (one of two, 50%) and risankizumab (one of one, 100%). Adalimumab yielded a partial response for two of three patients (67%). Combination therapy with systemic agents appeared to improve outcomes. Tildrakizumab had the shortest mean TTPR (6.8 weeks). Adverse effects were rare but led to treatment discontinuation in three patients. Sequential biologic therapy demonstrated some benefit to those who did not initially respond. These findings highlight the need for standardized treatment outcome measures and further research in PRP treatment.<\/jats:p>","DOI":"10.1093\/ced\/llaf246","type":"journal-article","created":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T07:32:18Z","timestamp":1749367938000},"page":"2240-2244","source":"Crossref","is-referenced-by-count":2,"title":["Treatment of refractory pityriasis rubra pilaris with biologic therapy: a case series"],"prefix":"10.1093","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-5034-6025","authenticated-orcid":false,"given":"Richard","family":"Han","sequence":"first","affiliation":[{"name":"Department of Dermatology, Monash Health , Melbourne, VIC ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R","family":"Spratt","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Nursing and Health Sciences, Monash University , Melbourne, VIC ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Monash Health , Melbourne, VIC ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis Y X","family":"Lai","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Monash Health , Melbourne, VIC ,","place":["Australia"]},{"name":"Skin Health Institute , Melbourne, VIC ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senhong","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Monash Health , Melbourne, VIC ,","place":["Australia"]},{"name":"Faculty of Medicine, Nursing and Health Sciences, Monash University , Melbourne, VIC ,","place":["Australia"]},{"name":"Skin Health Institute , Melbourne, VIC ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,6,9]]},"reference":[{"key":"2025102707125063900_llaf246-B1","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s40257-017-0338-1","article-title":"A review on pityriasis rubra pilaris","volume":"19","author":"Wang","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"2025102707125063900_llaf246-B2","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/jdv.14761","article-title":"Pityriasis rubra pilaris: algorithms for diagnosis and treatment","volume":"32","author":"Roenneberg","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025102707125063900_llaf246-B3","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1177\/1203475419887731","article-title":"Use of biologics in pityriasis rubra pilaris refractory to first-line systemic therapy: a systematic review","volume":"24","author":"Naidoo","year":"2020","journal-title":"J Cutan Med Surg"},{"key":"2025102707125063900_llaf246-B4","first-page":"923","article-title":"Emerging role of biologic drugs targeting IL-17 and IL-23: pityriasis rubra pilaris","volume":"14","author":"Potestio","year":"2024","journal-title":"Life Basel Switz"},{"key":"2025102707125063900_llaf246-B5","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1001\/jamadermatol.2020.0932","article-title":"Evaluation of ixekizumab treatment for patients with pityriasis rubra pilaris: a single-arm trial","volume":"156","author":"Haynes","year":"2020","journal-title":"JAMA Dermatol"},{"key":"2025102707125063900_llaf246-B6","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/bjd.21708","article-title":"Secukinumab for the treatment of adult-onset pityriasis rubra pilaris: a single-arm clinical trial with transcriptomic analysis","volume":"187","author":"Boudreaux","year":"2022","journal-title":"Br J Dermatol"},{"key":"2025102707125063900_llaf246-B7","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.ad.2024.02.019","article-title":"Pityriasis rubra pilaris: a multicentric case series of 65 Spanish patients","volume":"115","author":"Montero-Men\u00e1rguez","year":"2024","journal-title":"Actas Dermosifiliogr"},{"key":"2025102707125063900_llaf246-B8","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1177\/12034754231223159","article-title":"Updates on pityriasis rubra pilaris: a scoping review","volume":"28","author":"Zhou","year":"2024","journal-title":"J Cutan Med Surg"},{"key":"2025102707125063900_llaf246-B9","first-page":"e41125","article-title":"The effectiveness of anti-interleukin-17A treatment for pityriasis rubra pilaris: a systematic review","volume":"15","author":"Abduljawad","year":"2023","journal-title":"Cureus"},{"key":"2025102707125063900_llaf246-B10","first-page":"243","article-title":"Systemic therapies of pityriasis rubra pilaris: a systematic review","volume":"17","author":"Kromer","year":"2019","journal-title":"J Dtsch Dermatol Ges"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llaf246\/63455986\/llaf246.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/11\/2240\/63455986\/llaf246.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/11\/2240\/63455986\/llaf246.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:12:58Z","timestamp":1761563578000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/50\/11\/2240\/8158675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,9]]},"references-count":10,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,6,9]]},"published-print":{"date-parts":[[2025,10,27]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llaf246","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,6,9]]}}}